Niccine(R), a Nicotine Vaccine, for Relapse Prevention: A Phase II, Randomized, Placebo-Controlled, Multicenter Clinical Trial

Abstract

This nicotine vaccine appeared well tolerated but did not influence trajectories of relapse possibly because of insufficient antibody levels or lack of efficacy of the vaccine concept for relapse prevention.

Nicotine and Tobacco as Substances of Abuse in Children and Adolescents

“…The serum nicotine-specific antibody titers induced by the vaccine vary greatly. 95 This variability means that a substantial number of nonresponders have low antibody titers that are not likely to be effective. Currently, the evidence does not show success with long-term smoking cessation with currently available vaccines.…”

Nicotine vaccination—does it have a future?

“…In two studies with full results available, posthoc analyses detected higher cessation rates in participants with higher levels of nicotine antibodies, but these findings are not readily generalizable. Recently, Niccine has also failed to demonstrate an effect on relapse prevention (defined as preventing smokers who have successfully quit from relapsing to smoking) [9].…”

Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking

“…There has been no difference in results between vaccine and placebo groups in the various clinical trials of the past decade. Surprisingly, and despite the inefficacy of NV, many smokers managed to quit when smoking cessation medication (varenicline) and counselling were offered on top of the experimental product (Tonstad et al, 2013;Hoogsteder et al, 2014). For instance, in our case study, one of three participants ceased to smoke.…”